Nutrition Message Board - Msg: 19669502

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nutrition

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who started this subject	1/8/2004 4:13:45 PM
From: nigel bates	of 577

Lonza Prevails in Patent Infringement Lawsuit Against Axel and Stauber Thursday January 8, 3:40 pm ET FAIR LAWN, N.J., Jan. 8 /PRNewswire/ -- Lonza announces the settlement of their patent infringement actions against Axel Chemicals LLC ("Axel") in the U.S. District Court for the District of New Jersey and Stauber Performance Ingredients Inc. ("Stauber") in the U.S. District Court for the Central District of California. As part of the settlements, Axel and Stauber agree to refrain from infringing Lonza's L-carnitine L-tartrate patent. In addition, each party paid an undisclosed sum for past infringement of Lonza's patent rights. Lonza is an industry leader in developing innovative technology on the nutritional uses of L-carnitine and has an extensive patent portfolio covering these advances. These lawsuits and their favorable settlement are a significant step in protecting Lonza's intellectual property rights. The Axel and Stauber agreements mark the settlement of the last of four patent infringement lawsuits filed to protect its patent rights, all successfully concluded for Lonza. Lonza is a Life Sciences driven company headquartered in Switzerland, with sales of CHF 2.54 billion in 2002 and operating 18 production and R&D facilities in 8 countries. It employs 6200 people worldwide and is the leading custom manufacturer of active chemical ingredients, intermediates and biotechnology solutions to the pharmaceutical and agrochemical industries. It also offers organic intermediates for a wide range of applications and provides antimicrobial and associated products as well as polymer intermediates and compounds. For more information on Lonza please visit the company's website at www.lonza.com. For further information please visit www.carnitine.com.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next